Holen Sie sich die Stockscreener-App
24.40
2.05%
0.49
Schlusskurs vom Vortag:
$23.91
Offen:
$24.35
24-Stunden-Volumen:
282.58K
Relative Volume:
0.94
Marktkapitalisierung:
$617.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-2.94%
1M Leistung:
+15.26%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$23.97
$25.60
1-Wochen-Bereich:
$22.20
$25.60
52-Wochen-Spanne:
$13.36
$25.60
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Firmenname
Lb Pharmaceuticals Inc
Sektor
Branche
Telefon
917-450-6581
Adresse
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
24.40 | 604.90M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Eingeleitet | Roth Capital | Buy |
| 2025-10-06 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-06 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-06 | Eingeleitet | Stifel | Buy |
Lb Pharmaceuticals Inc Aktie (LBRX) Neueste Nachrichten
LB Pharmaceuticals to Participate in Upcoming March Investor Events - Bitget
Biotech developing schizophrenia therapies lines up March investor pitch - Stock Titan
LBRX SEC FilingsLB Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week HighTime to Buy? - MarketBeat
JPMorgan Chase & Co. Buys Shares of 1,032,603 LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals Inc's (NASDAQ:LBRX) Lock-Up Period Set To End on March 10th - MarketBeat
LB Pharmaceuticals Inc’s (NASDAQ:LBRX) Lock-Up Period Set To End on March 10th - Defense World
LBRX Technical Analysis & Stock Price Forecast - Intellectia AI
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - marketscreener.com
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 12-Month HighHere's Why - MarketBeat
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of “Hold” by Analysts - Defense World
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New LB Pharmaceuticals lawyer gets 140,000 stock options at $24.22 - Stock Titan
Neuro drug developer LB Pharma seeks $300M+ valuation in U.S. IPO - MSN
LB Pharmaceuticals stock rises on $100M financing - MSN
LB Pharmaceuticals announces $100.0 million private placement - marketscreener.com
LB Pharmaceuticals Announces $100 Million Private Placement Financing - TipRanks
LB Pharmaceuticals Signs Multiple Material Agreements - TradingView
Lb Pharmaceuticals Announces $100.0 Million Private Placement - TradingView
LB Pharmaceuticals Announces $100.0 Million Private Placement - The Manila Times
Sector Update: Health Care - marketscreener.com
LB Pharmaceuticals Advances LB-102 Into Long-Term Phase 3 Safety Study for Schizophrenia - TipRanks
LB Pharmaceuticals initiates phase 2 trial for bipolar depression drug By Investing.com - Investing.com Australia
LB Pharmaceuticals initiates Phase 2 trial of LB-102 - Yahoo Finance
LB Pharmaceuticals (NASDAQ:LBRX) Shares Down 6.4%Time to Sell? - MarketBeat
LB Pharmaceuticals initiates phase 2 trial for bipolar depression drug - Investing.com
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in - GlobeNewswire
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program - Sahm
LB Pharmaceuticals Advances LB-102 Into Phase 3, Setting Up a Key Schizophrenia Catalyst for Investors - TipRanks
LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week HighWhat's Next? - MarketBeat
LB Pharmaceuticals appoints Minako Pazdera as general counsel By Investing.com - Investing.com Nigeria
FDA clears Lexicon’s pilavapadin to advance to Phase 3 trials By Investing.com - Investing.com Nigeria
FDA clears Lexicon’s pilavapadin to advance to Phase 3 trials - Investing.com
LB Pharmaceuticals appoints Minako Pazdera as general counsel - Investing.com
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel - manilatimes.net
Viatris launches heart failure drug Inpefa in UAE, first outside US - Investing.com
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Trading Down 5.5%What's Next? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Up 7.7%Time to Buy? - MarketBeat
Two new leaders at LB Pharmaceuticals receive stock options - Stock Titan
LB Pharmaceuticals (NASDAQ:LBRX) Coverage Initiated at Roth Capital - Defense World
LB Pharmaceuticals (NASDAQ:LBRX) Stock Rating Upgraded by Roth Capital - MarketBeat
Roth/MKM initiates LB Pharmaceuticals stock with Buy rating on schizophrenia drug potential - Investing.com Australia
Roth/MKM initiates LB Pharmaceuticals stock with Buy rating on schizophrenia drug potential By Investing.com - Investing.com South Africa
Finanzdaten der Lb Pharmaceuticals Inc-Aktie (LBRX)
Es liegen keine Finanzdaten für Lb Pharmaceuticals Inc (LBRX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):